ICU Medical (ICUI)

• Market cap: $3.85B
• 1 day: -3.61%
• 5 days: -0.90%
• 1 month: -5.76%
• 3 months: -6.86%
• 6 months: -0.03%
• Year to date: -0.46%
• 1 year: 50.94%
• 5 years: -27.10%
• 10 years: 78.70%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Employees: 14,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

85% more call options, than puts

Call options by funds: $10.7M | Put options by funds: $5.79M

11% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 38

2% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 95

1% less funds holding

Funds holding: 285 [Q3] → 281 (-4) [Q4]

3.62% less ownership

Funds ownership: 102.1% [Q3] → 98.48% (-3.62%) [Q4]

17% less capital invested

Capital invested by funds: $4.53B [Q3] → $3.74B (-$788M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 0 (-4) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $200 27% upside
• Avg. target: $200 27% upside
• High target: $200 27% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Michael Toomey 0% 1-year accuracy 0 / 1 met price target

27% upside $200

Buy Upgraded

11 Dec 2024